Table 4

Modelled treatment sequences in cost-effectivenes analyses investigating first-line TNFi use

Modelled treatment sequences
Study, PYRInitial optionsInitial treatmentSubsequent treatment 1Subsequent treatment 2
Choi et al 2002205ETA mono
LEF
MTX
SSZ
No drug
Spalding 2006295ADA mono‘Pooled drug’
ETA mono‘Pooled drug’
ADA+MTX‘Pooled drug’
IFX+MTX‘Pooled drug’
MTX‘Pooled drug’
Chen et al286ADA monoMTX
ETA monoMTX
ADA+MTXSSZ
ETA+MTXSSZ
IFX+MTXSSZ
‘DMARDs’
Fautrel et al 200831 (AB)3ETA+MTXMTX+IFXMTX+RTXMTX+ABAsalv
MTX+SSZETA+MTXMTX+ADAMTX+RTXMTX+ABAsalv
MTXSSZLEFMTX+SSZMTX+RTXsalv
Davies et al 2009325MTXMTX+HCQLEFgoldpallpallpall
ADA+MTXMTX+HCQLEFgoldpallpallpall
ETA monoMTX+HCQLEFgoldpallpallpall
IFX+MTXMTX+HCQLEFgoldpallpallpall
ADA+MTXETA monoMTX+HCQLEFpallpallpall
Finckh et al 2009215NSAIDsDMARD
DMARD
NSAIDsDMARD*3TNFi
DMARD*3TNFi
TNFi1+MTXTNFi2+MTXTNFi3+MTX
  • ABA, abatacept; ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; IFX, infliximab; LEF, leflunomide; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; pall, palliative treatment; PYR, year of publication; salv, salvage treatment; SSZ, sulfasalazine; TNFi, TNFα inhibitors.